{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:47:10Z","timestamp":1761518830922,"version":"3.32.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2006,10,10]],"date-time":"2006-10-10T00:00:00Z","timestamp":1160438400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1038\/sj.bjc.6603347","type":"journal-article","created":{"date-parts":[[2006,10,10]],"date-time":"2006-10-10T08:23:37Z","timestamp":1160468617000},"page":"1161-1166","source":"Crossref","is-referenced-by-count":49,"title":["Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline\/taxane-based chemotherapy"],"prefix":"10.1038","volume":"95","author":[{"given":"M","family":"Campone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Cortes-Funes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Vorobiof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C F","family":"Slabber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Bourbouloux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Mendiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F M","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Colin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Aslanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Fumoleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,10,10]]},"reference":[{"key":"BF6603347_CR1","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1093\/annonc\/mdg174","volume":"14","author":"J Bennouna","year":"2003","unstructured":"Bennouna J, Fumoleau P, Armand JP, Raymond E, Campone M, Delgado FM, Puozzo C, Marty M (2003) Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 14: 630\u2013637","journal-title":"Ann Oncol"},{"key":"BF6603347_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","volume":"17","author":"JL Blum","year":"1999","unstructured":"Blum JL, Jones SE, Buzdar AU, Lorusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485\u2013493","journal-title":"J Clin Oncol"},{"key":"BF6603347_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/sonc.2003.37267","volume":"30","author":"H Calvert","year":"2003","unstructured":"Calvert H (2003) Pemetrexed (Alimta) a promising new agent for the treatment of breast cancer. Semin Oncol 30: 2\u20135","journal-title":"Semin Oncol"},{"key":"BF6603347_CR4","doi-asserted-by":"publisher","first-page":"8576","DOI":"10.1021\/ja971864w","volume":"119","author":"J Fahy","year":"1997","unstructured":"Fahy J, Duflos A, Ribet JP, Jacquesy JC, Berrier C, Jounnetaud MP, Zunino F (1997) Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc 119: 8576\u20138577","journal-title":"J Am Chem Soc"},{"key":"BF6603347_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/2530297","volume":"38","author":"TR Fleming","year":"1982","unstructured":"Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143\u2013151","journal-title":"Biometrics"},{"key":"BF6603347_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ejca.2003.11.007","volume":"40","author":"P Fumoleau","year":"2004","unstructured":"Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Cure H, Vuillemin E, Morere JF, Montestruc F, Mouri Z, Namer M (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40: 536\u2013542","journal-title":"Eur J Cancer"},{"key":"BF6603347_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00944177","volume":"10","author":"S Green","year":"1992","unstructured":"Green S, Weiss GR. (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10: 239\u2013253","journal-title":"Invest New Drugs"},{"key":"BF6603347_CR8","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1200\/JCO.2005.10.034","volume":"23","author":"A Hamilton","year":"2005","unstructured":"Hamilton A, Hortobagyi G (2005) Chemotherapy: what progress in the last 5 years. J Clin Oncol 23: 1760\u20131775","journal-title":"J Clin Oncol"},{"key":"BF6603347_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000069315","volume":"64","author":"V Heinemann","year":"2003","unstructured":"Heinemann V (2003) Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 64: 191\u2013206","journal-title":"Oncology"},{"key":"BF6603347_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S0959-8049(98)00416-X","volume":"35","author":"BT Hill","year":"1999","unstructured":"Hill BT, Fiebig HH, Waud WR, Poupon MF, Colpaert F, Kruczynski A (1999) Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 35: 512\u2013520","journal-title":"Eur J Cancer"},{"key":"BF6603347_CR11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000425849","volume":"54","author":"A Kruczynski","year":"1999","unstructured":"Kruczynski A, Astruc J, Ricome C, Colpaert F, Hill BT (1999) Definite antitumour activity of vinflunine, a novel fluorinated vinca alkaloid, against human tumour xenografts. Contrib Oncol Basel Karger 54: 369\u2013378","journal-title":"Contrib Oncol Basel Karger"},{"key":"BF6603347_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0006-2952(97)00505-4","volume":"55","author":"A Kruczynski","year":"1998","unstructured":"Kruczynski A, Barret JM, Eti\u00e9vant C, Colpaert F, Fahy J, Hill BT (1998) Antimitotic and tubulin-interacting properties of vinflunine, a novel vinca alkaloid. Biochem Pharmacol 55: 635\u2013648","journal-title":"Biochem Pharmacol"},{"key":"BF6603347_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/sj.bjc.6600025","volume":"86","author":"A Kruczynski","year":"2002","unstructured":"Kruczynski A, Eti\u00e9vant C, Perrin D, Chansard N, Duflos A, Hill BT (2002) Characterization of apoptosis induced by vinflunine, the most recent vinca alkaloid in clinical development. BJC 86: 143\u2013150","journal-title":"BJC"},{"key":"BF6603347_CR14","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.1997.15.4.1395","volume":"15","author":"RB Livingston","year":"1997","unstructured":"Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, Adamkiewicz BB, Long CA (1997) Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15: 1395\u20131400","journal-title":"J Clin Oncol"},{"key":"BF6603347_CR15","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0026-895X(24)13258-0","volume":"53","author":"S Lobert","year":"1998","unstructured":"Lobert S, Ingram JW, Hill BT, Correia JJ (1998) A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 53: 908\u2013915","journal-title":"Mol Pharmacol"},{"key":"BF6603347_CR16","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1200\/JCO.2005.10.024","volume":"23","author":"JA Low","year":"2005","unstructured":"Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, Poruchynsky MS, Steinberg SM, Mannan N, Fojo T, Swain SM (2005) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23: 2726\u20132734","journal-title":"J Clin Oncol"},{"key":"BF6603347_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1124\/mol.60.1.225","volume":"60","author":"VK Ngan","year":"2001","unstructured":"Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA (2001) Mechanism of mitotic block and inhibition of cell proliferation by semisynthetic vinca alkaloids vinorelbine and its new derivative vinflunine. Mol Pharmacol 60: 225\u2013232","journal-title":"Mol Pharmacol"},{"key":"BF6603347_CR18","first-page":"5045","volume":"60","author":"VK Ngan","year":"2000","unstructured":"Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA, Wilson L (2000) Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 60: 5045\u20135051","journal-title":"Cancer Res"},{"key":"BF6603347_CR19","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.2004.10.047","volume":"22","author":"EA Perez","year":"2004","unstructured":"Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22: 2849\u20132855","journal-title":"J Clin Oncol"},{"key":"BF6603347_CR20","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/annonc\/mdg346","volume":"14","author":"P Reichardt","year":"2003","unstructured":"Reichardt P, Von Minckwitz G, Thusss-Patience PC, Jonat W, Kolbl H, Janicke F Kieback DG, Kuhn W, Schindler AE, Mahrmann S, Kaufmann M, Luck HJ (2003) Multicenter phase II study of oral capecitabine (Xeloda\u00ae) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14: 1227\u20131233","journal-title":"Ann Oncol"},{"key":"BF6603347_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1023\/A:1010679127390","volume":"66","author":"CH Smorenburg","year":"2001","unstructured":"Smorenburg CH, Bontenbal M, Seynaeve C, Van Zuylen C, de Heus G, Verweij J, de Wit R (2001) Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66: 83\u201387","journal-title":"Breast Cancer Res Treat"},{"key":"BF6603347_CR22","unstructured":"World Health Organization (1979) WHO handbook for reporting results for cancer treatment. Geneva: World Health Organization"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6603347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603347","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T09:50:18Z","timestamp":1736589018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6603347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,10]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["BF6603347"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6603347","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2006,10,10]]}}}